Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hell yeah! Covid19 therapeutics market size will reach 20B.
That's dumbest thing I have ever seen
Imun owned 15% of cytocom shares. Very simple to understand.
Lol you are joke Noreen owns 15M shares of imun and she probably own less shares on cytcome.
You are sharing old information. Cytocom, Inc. Announces Agreement to Reacquire Rights to Lead Drug Candidate CYTO-201 and CYTO-401 in Emerging Markets
No imun don't own the rights international. Cytcoma acquired the international rights from imun for 5M
Newbie posted old information
This is old information. The equity stake is 14.6% on Cytocom and all international rights were sold back to Cytocom for $5M.
Agreed! This will open the door for other private companies to approach imun for reverse merger.
Wow after gone for 6 months, you are back with your nonsense.
"This is the ONLY way CBLI will approve of this merger. They only have 16M O/S, IMUN has 460M shares." Imun is only stake holder in Cytocom not on cbli. Nowhere on the 8K mentioned RS.
Post merger cbli will be named Cytocom. Cytocom will own 51% imun will own 10% and cbli share holders will own 39%
Okay that your interpretation and not a big deal
“the resignation was due to disagreements between Mr. Handley and the Board on strategic direction and related milestones. The Board has assembled an experienced management transition team to formulate and execute a strategy for long term viability of the Company to benefit its shareholders.”
Handley was fired by the board of directors
actually the website is working. https://www.immunetherapeutics.com
bad blood between Kevin & Micheal. It could happen but I don’t think it will happen.
I doubt it will be Cytocom but I do believe OyaGen could merge with imun.
Form D is very important 15m private offering &2.27 already invested is very bullish.
The clinical data are only disclosed to the investors etc the people who invested $2.5m or future investors. Cytocom doesn’t benefit from making the information public.
You have public company doing clinical trial undisclosed indications for competitive reason until proof of concept is established.
I’m talking about internal testing before doing clinical trial.
Don’t forget cytocom is private company not required to release any clinical data until proof of concept is established.
Ambs ownership in EMOR is 33m shares of preferred stock
Ambs Amarantus is receiving Emerald Preferred Stock that could be worth $66M In 2022.
You forgot to mentioned Amarantus is receiving Emerald Preferred Stock that could be worth $66M in 2022.
Thanks that don’t make sense. They should issue more shares to ambs
They own 49% per the agreement
Why 85m shares ? I though 49%